|
業務類別
|
Biotechnology |
|
業務概覽
|
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome. |
| 公司地址
| 3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247 |
| 電話號碼
| +1 214 612-0000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tayshagtx.com |
| 員工數量
| 73 |
| Mr. Sean P. Nolan |
Chairman of the Board and Chief Executive Officer |
美元 621.00K |
21/04/2025 |
| Dr. Sukumar Nagendran, M.D. |
Director, President and Head, Research and Development |
美元 584.78K |
21/04/2025 |
| Mr. Kamran Alam, C.P.A. |
Corporate Secretary, Chief Financial Officer and Principal Accounting Officer |
美元 455.13K |
21/04/2025 |
|
|
| Mr. Phillip B. Donenberg |
Independent Director |
21/04/2025 |
| Mr. Sean P. Nolan |
Chairman of the Board and Chief Executive Officer |
21/04/2025 |
| Mr. Sean Stalfort |
Independent Director |
21/04/2025 |
| Dr. Sukumar Nagendran, M.D. |
Director, President and Head, Research and Development |
21/04/2025 |
| Dr. Laura Sepp-Lorenzino, PhD |
Independent Director |
21/04/2025 |
| Dr. Alison S. Long, M.D.,PhD |
Independent Director |
21/04/2025 |
|
|
|
|
